Anthem · Tirzepatide · US health-plan appeal rights

Tirzepatide denied as non-formulary by Anthem?

Q: How long do I have to appeal a Anthem Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Non-formulary doesn't mean uncoverable. Most plans have a formulary-exception process: the appeal needs to show the formulary alternatives are inappropriate for your specific clinical situation.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Anthem typically requires

HbA1c ≥6.5% within 12 months OR existing T2DM diagnosis.

Source policy: Anthem tirzepatide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Anthem angle on Tirzepatide

## Non-Formulary Denials for Tirzepatide Under Anthem BCBS

A non-formulary denial on tirzepatide (Mounjaro/Zepbound) from Anthem is not a clinical rejection — it is a formulary tier exclusion, meaning the molecule sits outside Anthem's preferred PDL and requires a Non-Formulary Exception (NFE) rather than a standard prior authorization. Conflating the two is the single most common reason appeals fail on first pass. Anthem's pharmacy benefit is administered by CarelonRx (formerly IngenioRx), and NFE requests route through CarelonRx's exceptions queue, not Anthem's medical PA portal. Submitting on the wrong channel triggers an automatic procedural denial that does not toll your appeal clock under 29 CFR §2560.503-1(f)(2)(i).

For T2DM indications, Anthem's Clinical UM Guideline CG-DRUG-141 (Glucose-Lowering Agents) and PA Criteria PA.PCSK.196 govern tirzepatide. The plan's stated coverage threshold — HbA1c ≥6.5% within 12 months OR documented T2DM diagnosis — is the medical necessity layer. A non-formulary denial sits on top of that: even with HbA1c documented, CarelonRx will reject unless you affirmatively invoke the NFE pathway and demonstrate that all formulary alternatives (semaglutide/Ozempic, dulaglutide/Trulicity, liraglutide/Victoza, and the SGLT2 class) have been tried and failed, are contraindicated, or are expected to be inferior based on patient-specific factors.

The statutory hook is ERISA §503 and 29 CFR §2560.503-1(g)(1)(v)(A), which requires the plan to disclose the specific internal rule or formulary criterion relied upon. Demand the CarelonRx formulary exclusion code and the version of CG-DRUG-141 applied. If the denial letter cites only "non-formulary" without naming the alternative drugs the patient must fail, that is a disclosure defect appealable on procedural grounds alone. For self-funded ERISA plans, also invoke 29 USC §1185d (step-therapy exception standards under the Consolidated Appropriations Act) where a prior trial of semaglutide caused intolerance, contraindication, or inadequate glycemic response.

Fully-insured Anthem members in California, New York, and Texas have additional state-law leverage: California's Knox-Keene §1367.241 and New York Insurance Law §4903 both compress external review timelines and shift the burden of proof on formulary exceptions to the insurer once a treating physician attests medical necessity.

Tactical tip: File the NFE through CarelonRx's provider portal (not the member appeals fax), explicitly check the "formulary exception" box (not "PA reconsideration"), and attach a one-page letter of medical necessity that (1) names CG-DRUG-141 by version, (2) lists each formulary GLP-1/SGLT2 alternative with a dated trial-and-failure or contraindication, and (3) cites the patient's most recent HbA1c with lab date. If denied again, immediately request the Anthem Grievance and Appeals Level 2 review with simultaneous IRO/external review filing — Anthem frequently overturns at IRO when CarelonRx's internal queue does not.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Anthem appeals

Other insurers on Tirzepatide

Other denial reasons for Anthem Tirzepatide

denied as not medically necessary denied for failing step therapy denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.